CASI Pharmaceuticals (CASI) to Release Earnings on Monday

CASI Pharmaceuticals (NASDAQ:CASI) is anticipated to release its results before the market opens on Monday, March 30th. Analysts expect CASI Pharmaceuticals to post earnings of ($0.36) per share for the quarter.

CASI Pharmaceuticals Price Performance

Shares of CASI Pharmaceuticals stock opened at $0.21 on Monday. The stock has a market capitalization of $2.55 million, a P/E ratio of -0.07 and a beta of 0.91. The business has a 50 day simple moving average of $0.67 and a two-hundred day simple moving average of $1.13. CASI Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $3.09.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of CASI Pharmaceuticals by 2,013.3% during the 3rd quarter. Bank of America Corp DE now owns 254,884 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 242,823 shares during the last quarter. Woodline Partners LP grew its holdings in shares of CASI Pharmaceuticals by 64.9% in the first quarter. Woodline Partners LP now owns 164,365 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 64,675 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in CASI Pharmaceuticals during the third quarter worth about $55,000. Hedge funds and other institutional investors own 22.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CASI Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CASI Pharmaceuticals has an average rating of “Hold” and an average price target of $4.00.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers.